Mode
Text Size
Log in / Sign up
Phase 4 N=40 Randomized Triple-blind Basic Science

Duloxetine in Osteoarthritis (OA) Pain

Osteoarthritis

Enrolled (actual)
40
Serious AEs
0.0%
Results posted
Dec 2014
Primary outcome: Primary: Change in Brain Gray Matter Volume — -0.34; -0.92 percentage of change

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
Duloxetine (Drug); Sugar pill (Drug)
Age
Adult, Older Adult · 40+ yrs
Sex
All
Sponsor
Northwestern University
Primary completion
Apr 2014

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in Brain Gray Matter Volume
-0.34; -0.92
SECONDARY
Change in Pain Magnitude
8.3; 8.7

Summary

This study aims to determine in people with knee Osteoarthritis (OA) if relief of pain after treatment with either duloxetine or placebo is associated with changes in brain anatomy.

Eligibility Criteria

Inclusion Criteria

  • Age: 45-80 years
  • ACR criteria for OA including Kellgren-Lawrence radiographic OA grades II-IV
  • VAS pain score >5/10 within 48 hrs of the phone screen and visit 1 (Screening)
  • Knee OA for a minimum of 12 months
  • Need for daily pain medication to manage symptoms of OA

Exclusion Criteria

Currently taking MAO inhibitors or any centrally acting drug for analgesia, depression

  • Narrow angle glaucoma
  • Uncontrolled hypertension
  • Co-existing inflammatory arthritis, fibromyalgia or other chronic pain state.
  • If a female, pregnant, trying to become pregnant, or lactating
  • Major depressive disorder
  • Substantial alcohol use or history of significant liver disease
  • Use of MAO inhibitors, triptans, serotonin precursors (tryptophan)
  • Use of potent CYP1A2 inhibitors, Thioridazine, and anti-depressants
  • Diabetes, type 1 or type 2
  • Condition in which the Investigator believes would interfere with the subject's ability to comply with study instructions, or might confound the interpretation of the study results or put the subject at undue risk
  • MRI safety necessitates the exclusion of subjects having one or more of the following:
  • Metal fragments in the eye or face, or having worked previously in the metal industry
  • Implantation of any electronic devices such as (but not limited to) cardiac pacemakers, cardiac, defibrillators, and cochlear implants or nerve stimulators.
  • Surgery on the blood vessels of the brain
  • Claustrophobia (fear of enclosed places)
  • Piercings or tattoos
  • More than 250 lbs in weight
  • Obvious brain abnormalities
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01558700). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search